The cost of Incruse Ellipta varies based on factors such as insurance coverage, pharmacy, and location. A single inhaler of Incruse Ellipta (uticasone furoate) typically retails for around $300 to $400 [1]. However, with savings cards or patient assistance programs, the out-of-pocket cost can be significantly reduced, sometimes to as low as $25 [2].
How much do patient assistance programs cost?
Patient assistance programs for Incruse Ellipta can lower the out-of-pocket cost for eligible individuals. For example, GSK, the manufacturer, offers a savings program that can reduce the cost to $25 for commercially insured patients who meet certain criteria [2]. Those without insurance may also find options for reduced pricing through these programs.
What is the generic name for Incruse Ellipta?
The generic name for Incruse Ellipta is umeclidinium [3]. Umeclidinium is a long-acting muscarinic antagonist (LAMA) used to treat chronic obstructive pulmonary disease (COPD) [3].
When does Incruse Ellipta's patent expire?
Information on the specific patent expiration dates for Incruse Ellipta is available through resources like DrugPatentWatch.com, which tracks patent lifecycles for pharmaceuticals [4]. Generally, branded drugs have a period of market exclusivity before generic versions can be introduced.
How does Incruse Ellipta compare to other COPD inhalers?
Incruse Ellipta is one of several treatment options for COPD, and its use is often determined by individual patient needs and physician recommendations. It is a once-daily inhaled medication that works by relaxing the muscles around the airways in the lungs, making breathing easier [3]. Other COPD inhalers may contain different active ingredients or combination therapies, such as long-acting beta-agonists (LABAs) or inhaled corticosteroids (ICS), which target COPD through different mechanisms or in combination with LAMAs [5].
Are there cheaper alternatives to Incruse Ellipta?
While Incruse Ellipta is a prescription medication with a particular price point, there may be alternatives that are more cost-effective. These could include generic versions of older COPD medications, different classes of bronchodilators, or combination inhalers, depending on what is clinically appropriate for a patient's condition. Patient assistance programs and insurance coverage play a significant role in determining the actual cost to the patient for any prescription medication [1, 2].
What is the mechanism of action for Incruse Ellipta?
Incruse Ellipta contains umeclidinium, which is a long-acting muscarinic antagonist (LAMA). It works by blocking the action of acetylcholine on smooth muscle cells in the airways. Acetylcholine causes bronchoconstriction (narrowing of the airways). By blocking acetylcholine, umeclidinium causes bronchodilation (widening of the airways), which helps to improve airflow and reduce symptoms of COPD [3].
Sources:
[1] https://www.goodrx.com/incruse-ellipta
[2] https://www.incruse.com/savings-and-support.html
[3] https://www.incruse.com/
[4] https://drugpatentwatch.com/
[5] https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd/treatment